Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

53 results about "Viral entry" patented technology

Viral entry is the earliest stage of infection in the viral life cycle, as the virus comes into contact with the host cell and introduces viral material into the cell. The major steps involved in viral entry are shown below. Despite the variation among viruses, there are several shared generalities concerning viral entry.

Envelope glycoprotein for transduction of NK cell pseudotyped lentiviral vector and application thereof

The invention discloses an envelope glycoprotein for packaging a transduction NK cell pseudotyped lentiviral vector and application of the envelope glycoprotein. The envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasm region, wherein the amino acid sequence or the mutation sequence of the extracellular region is as shown in SEQ ID NO: 1 or SEQ ID NO: 2; an amino acid sequence or a mutation sequence of the transmembrane region is as shown in SEQ ID NO: 3 or SEQ ID NO: 4; an amino acid sequence or a mutation sequence of the cytoplasmic region is shown as SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. The BaEV envelope glycoprotein mutant replaces VSV-G to package lentivirus pseudovirus, the high virus titer 7.33 E + 07 TU / mL is maintained, the NK cells can be effectively recognized, the virus can be mediated to enter the cells, and therefore the purpose of efficiently transfecting the NK cells is achieved.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD

Algin sulfate (PMGS) patch as well as preparation method and application thereof

The invention relates to an algin sulfate (PMGS) patch as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the application, the fucoidan polysaccharide sulfate (PMGS) is used as a main raw material of the microneedle for the first time, the needle tip is completely composed of PMGS, the PMGS plays a role in medicine and adjuvant integration, on one hand, the PMGS is used as a needle tip matrix to provide enough mechanical strength to pierce warts and surrounding skin and is more suitable for related warts with obvious skin thickening, and on the other hand, the PMGS is diffused and released at the position where viruses are located, so that the effect of preventing and treating warts is achieved. The skin wart treatment effect is achieved by preventing virus from entering and enhancing skin immunity, compared with a previous authorized patent scheme, the problems that PMGS as macromolecular polysaccharide enters the skin and is insufficient in absorption are solved in a microneedle mode, PMGS can be directly delivered to basal layer cells where HPV is located, and fixed-point drug delivery is achieved.
Owner:OCEAN UNIV OF CHINA

Probe device for gene mutation detection

The utility model belongs to the technical field of medical treatment, and discloses a probe device for gene mutation detection, which comprises a protective cylinder, a battery box is fixedly mounted at the top of the protective cylinder, a T-shaped rod is slidably mounted above an inner cavity of the protective cylinder, a piston attached to the inner cavity of the protective cylinder is fixedly mounted at the bottom of the T-shaped rod, and a sensing device is fixedly mounted at the bottom of the piston. A probe is fixedly installed at the bottom of the sensing device, a second wedge-shaped block can abut against a first wedge-shaped block to drive a sealing plate to move towards the outer side, then a channel of a through hole is opened till the probe penetrates out of the through hole, gene detection can be conducted, data are uploaded, and after detection is finished, a motor is started to drive a lead screw to rotate in the reverse direction. When the pile casing is in use, the sensing device, the probe and the inductor move upwards, at the moment, the first wedge-shaped block loses abutting connection with the second wedge-shaped block, under rebound reset of the spring, the sealing plate at the bottom of the first wedge-shaped block can be driven to move towards the inner side, then the through hole is sealed, and external bacteria and viruses are prevented from entering the pile casing to pollute the probe.
Owner:CHENGDU JIYU TECH CO LTD

Envelope glycoprotein for transduction of NK cell pseudotyped lentiviral vector and application thereof

The invention discloses an envelope glycoprotein for packaging a transduction NK cell pseudotyped lentiviral vector and application of the envelope glycoprotein. The envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasm region, wherein the amino acid sequence or the mutation sequence of the extracellular region is as shown in SEQ ID NO: 1 or SEQ ID NO: 2; an amino acid sequence or a mutation sequence of the transmembrane region is as shown in SEQ ID NO: 3 or SEQ ID NO: 4; an amino acid sequence or a mutation sequence of the cytoplasmic region is shown as SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. The BaEV envelope glycoprotein mutant replaces VSV-G to package lentivirus pseudovirus, the high virus titer 7.33 E + 07 TU / mL is maintained, the NK cells can be effectively recognized, the virus can be mediated to enter the cells, and therefore the purpose of efficiently transfecting the NK cells is achieved.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD

An anti-swine pseudorabies virus infection preparation and application of radix rehmanniae polysaccharides in preparation of the preparation

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.
Owner:YANGZHOU UNIV

Envelope glycoprotein for pseudotyped lentiviral vector for transduction of NK cells and use of envelope glycoprotein

Disclosed in the present invention are an envelope glycoprotein for packaging a pseudotyped lentiviral vector for transduction of NK cells and a use of the envelope glycoprotein. The envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasmic region, wherein the amino acid sequence or the mutation sequence of the extracellular region is as shown in SEQ ID NO: 1 or SEQ ID NO: 2; the amino acid sequence or the mutation sequence of the transmembrane region is as shown in SEQ ID NO: 3 or SEQ ID NO: 4; and the amino acid sequence or the mutation sequence of the cytoplasmic region is shown as SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. A BaEV envelope glycoprotein mutant replaces VSV-G to package a lentiviral pseudovirus, so that a high virus titer of 7.33E+07 TU / mL is maintained, NK cells can be effectively recognized, and entry of viruses into the cells can be mediated, thereby achieving the objective of efficiently transfecting the NK cells.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD

Antiviral cells and uses thereof

The present invention provides a mammalian cell line that has been genetically engineered to make it resistant to viral entry and / or replication; and provides a method for using the cell line to reduce or prevent viral contamination of a bioproduction system.
Owner:EMD MILLIPORE CORP

Epidemic prevention guarantee station and epidemic prevention fattening field

The utility model provides an epidemic prevention safeguard station and an epidemic prevention fattening yard, the epidemic prevention safeguard station comprises a three-section type dressing station and a disinfection station, the three-section type dressing station comprises two dressing rooms and a bath room, and personnel unidirectionally circulate in the three-section type dressing station; the disinfecting and killing station comprises a first buffer room, a wet type treatment room, a dry type treatment room and a second buffer room, the dry type treatment room and the wet type treatment room are located in the middle of the disinfecting and killing station, the first buffer room and the second buffer room are located at the two ends of the disinfecting and killing station respectively, and materials and vehicles unidirectionally circulate in the disinfecting and killing station; the wet-type treatment room comprises soaking equipment for soaking and disinfecting the materials, and the dry-type treatment room comprises drying equipment for drying the materials and further comprises irradiation equipment for irradiating and disinfecting the materials and the vehicles. According to the utility model, personnel, materials and vehicles are controlled, so that the possibility that germs and viruses enter the epidemic prevention fattening field is reduced, the occurrence and transmission of pig diseases are prevented, and the economic benefit of pig raising is improved.
Owner:WENS FOODSTUFF GROUP CO LTD

Use of navitoclax (ABT263) in the preparation of broad-spectrum antiviral inhibitors

The application relates to the field of biological medicine, and particularly relates to application of Navitoclax (ABT263) in preparation of a broad-spectrum antiviral inhibitor. The application of the compound Navitoclax (ABT263), an analogue or a salt thereof shown in formula (I) in preparation of a broad-spectrum antiviral inhibitor. It is found in the application that the compound has broad-spectrum antiviral activity, including but not limited to SARS-CoV-2, SARS-CoV, MERS-CoV, the compound can act on the virus entry stage, and the virus is resisted outside the target cell. In addition, the compound has a high selection index (CC50 / IC50) for different viruses, and has considerable safety. The application provides a broad-spectrum antiviral small-molecule compound, which has the advantages of simple preparation method, low cost, easy transportation and storage, high safety and good activity, and has a broad prospect in the fields of biological medicine and response to new emerging infectious diseases.
Owner:SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY

Viral Entry Inhibitors Derived From Botanicals

This disclosure relates to methods of treating a coronavirus infection or other microbial infection comprising administering an effective amount of a plant extract, or compound, or combination of compounds derived therefrom to a subject in need thereof. In certain embodiments, the plant extract is obtained by a process of contacting a segment of a plant a with a solvent providing an extract as reported herein. In certain embodiments, this disclosure contemplates pharmaceutical compositions comprising extracts and components contained therein for use in methods of treating viral or other microbial infections.
Owner:EMORY UNIVERSITY

A novel c3d4 human cell model for MERS and SARS-COV-2 infection

A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+ / TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.
Owner:HACKENSACK MERIDIAN HEALTH INC

Virus purification ultrafiltration centrifugal tube

The utility model discloses a virus purification ultrafiltration centrifuge tube, which relates to the technical field of centrifuge tubes and comprises an outer tube and an inner tube, a cover is arranged on the outer tube, a first fastening sleeve and a second fastening sleeve are arranged on the cover, one end of the first fastening sleeve is connected with one end of the second fastening sleeve through a hinge shaft, and a fixing block is arranged at the front end of the first fastening sleeve. The device is provided with a purification structure, viruses are purified for the first time through the first filter screen in the centrifugation process, the viruses enter the second filter screen and are purified for the second time through the centrifugal machine, meanwhile, filter holes of the second filter screen are smaller than filter holes of the third filter screen, and the residual viruses purified through the second filter screen enter the third filter screen; third purification is carried out through a third filter screen, the purified viruses are separated through an annular fixing sleeve in an outer tube, at the moment, a nut is screwed again to move on a threaded rod, a first fastening sleeve and a second fastening sleeve are separated, a cover is taken down, and the purified viruses are taken out through a needle tube.
Owner:RUIZHENG PHARM TECH (WUHAN) CO LTD

Method to improve macrophages functions

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Super mask (m.e.n.)

To provide a mask capable of: 100% completely preventing droplet infection of novel coronavirus in particular, including to the eyes; allowing wearers to have clear conversation, preventing a transparent plate and glasses from fogging; being usable by women without ruining makeup, being usable over a long period of time; etc.SOLUTION: A mask dedicated to novel coronavirus, is designed to enhance rigidity by bending a flat transparent plate to improve temperature and humidity, prevents virus entry by increasing internal temperature and atmospheric pressure humidity, completely blocks virus droplets from reaching the eyes, nose, and mouth without touching the eyes, nose, and mouth, expels exhaled air to prevent the transparent plate and glasses from fogging, allows wearers to have clear conversation, keeps women's makeup from coming off, can be put in a pocket, allows eating, doubles as an eye mask, is a world's first so-called face shield, and has a highest performance and widest range of uses.SELECTED DRAWING: Figure 4
Owner:DR NAKAMATS INNOVATION INST

Small molecules that treat or prevent viral infections

The invention relates to anti-viral compounds suitable for use in blocking virus entry into cells, and methods of blocking virus entry into cells by associating the cells with the anti-viral compounds. The associating may occur in vitro, or in vivo in a subject through administration of the anti-viral compounds to the subject. The invention also relates to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound. The subject may be a human being suffering from or vulnerable to the viral infection. The virus may include a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2).
Owner:UNIV HOUSTON SYST

A fermented traditional Chinese medicine preparation for treating porcine epidemic diarrhea virus infection and its application

This invention discloses a fermented traditional Chinese medicine preparation for treating porcine epidemic diarrhea virus infection and its application. This fermented traditional Chinese medicine preparation is obtained by fermenting dandelion, isatis root, alisma, kudzu root, scutellaria, licorice, and hawthorn using a probiotic mother liquor. The probiotic mother liquor contains *Lactobacillus rhamnoides*, *Bacillus subtilis*, *Lactobacillus plantarum*, and *Bacillus coagulans*. The preparation method of this fermented traditional Chinese medicine preparation includes the following steps: (1) mixing the herbs, decocting, filtering, and sterilizing to obtain a mixed herbal liquid; (2) adding the probiotic mother liquor to the mixed herbal liquid for fermentation to obtain the fermented traditional Chinese medicine liquid. This fermented traditional Chinese medicine preparation can exert its anti-porcine epidemic diarrhea virus effect in vitro by preventing the virus from entering cells, inhibiting viral replication, and directly killing the virus. It has a significant preventive and therapeutic effect on diseases caused by this virus, is easy to prepare, can be mass-produced, and is beneficial to improving the economic benefits of pig farms.
Owner:JILIN AGRICULTURAL UNIV

Avian infectious bronchitis virus system based on double reporter genes and application thereof

The invention relates to the technical field of gene engineering, in particular to an avian infectious bronchitis virus system based on double reporter genes and application thereof. According to the avian infectious bronchitis virus system based on the double reporter genes, real-time monitoring of IBV infection and replication can be achieved, the detection sensitivity and specificity are improved, meanwhile, experimental operation is simplified, and cost is reduced. The system can be used for various applications including but not limited to virus susceptible cell testing, virus entry mechanism research, antiviral drug screening, vaccine and neutralizing antibody effect evaluation, virus intrusion inhibitor evaluation and influence research of virus variation on infectivity. The system and the method provided by the invention provide a new tool for research and prevention and control of IBV and other enveloped viruses, and have important scientific and practical application values.
Owner:XIANGHU LABORATORY

A Chinese medicine composition and its application

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a Chinese medicine composition and its application. A Chinese medicine composition, characterized in that it is composed of an ephedra extract, a scutellaria extract and a liquorice extract. The present invention finds that the Chinese medicine composition can synergistically inhibit the invasion of SARS-CoV-2 pseudovirus into human epithelial cells and synergistically inhibit the production of inflammatory factors by macrophages. By preventing the virus from entering cells; preventing the virus from replicating in cells; inhibiting body inflammation; lowering body temperature; relieving cough; resolving phlegm, increasing the amount of airway secretions in the body, etc., it prevents and treats viral respiratory infections and improves related clinical symptoms. According to the prior art, ephedra, scutellaria or liquorice alone cannot effectively inhibit SARS-CoV-2. Based on this discovery, the present invention uses the Chinese medicine composition to prepare a drug for preventing and / or treating viral infections.
Owner:CHINA PHARM UNIV

C-based single domain antibody for neutralizing respiratory syncytial virus and application thereof

The present disclosure relates to a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present disclosure is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. The C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.
Owner:WUHAN BANKE BIOTECHNOLOGY CO LTD

Method for manufacturing a negative ion device for preventing and treating airborne viral infections.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.
Owner:シュウジア

Application of torreya grandis aril volatile oil in preparation of medicine for resisting porcine epidemic diarrhea virus

The invention relates to an application of torreya grandis aril volatile oil in preparation of a medicine for resisting porcine epidemic diarrhea virus. The torreya grandis aril volatile oil is volatile oil extracted from torreya grandis' Merrillii 'Hu aril of a torreya plant of taxus chinensis family. Researches show that the torreya grandis aril volatile oil can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicines for resisting the porcine epidemic diarrhea viruses. The torreya grandis aril volatile oil is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.
Owner:ZHEJIANG UNIV

Symmetry based viral antagonists

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.
Owner:CITY OF HOPE

Method to improve macrophages functions

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (HVEM) co-stimulatory domain and uses thereof

PCT designated stage expiredWO2024236547A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyHerpesvirus entry mediatorPhagocytic Cell
Provided herein are phagocytic cells genetically engineered to express a chimeric antigen receptor (CAR) having a co-stimulatory domain from a herpes virus entry mediator (HVEM) protein, along with related vectors, compositions, and methods which allow enhanced phagocytosis of target cells and treatment of conditions in a subject.
Owner:INCEPTOR BIO LLC

An anti-HPV virus fabric based on a graphene-based hollow sphere structure and a preparation method and application thereof

ActiveCN122707373BGraphite oxideChemistry
The application provides an anti-HPV virus fabric based on a graphene-based hollow sphere structure and a preparation method thereof. First, low-oxidation-degree graphene oxide nanosheets (carbon-oxygen ratio 3-10) and a sulfonic acid group-containing macromolecular aqueous solution are prepared, the amphiphilicity of the low-oxidation-degree graphene oxide is utilized, and a stable emulsion with graphene oxide as a shell and the sulfonic acid group-containing macromolecular aqueous solution as a core is constructed in n-hexane through ultrasonic shearing. The emulsion is atomized and sprayed on a fabric after low-temperature plasma treatment (so as to make the fabric positively charged), and after slow drying, an open hollow sphere structure is formed. The internal sulfonic acid group acts as a trapping agent to attract viruses, the shell graphene oxide sharp edge physically disturbs and cuts the virus capsid, a three-level synergistic mechanism of "trapping-enrichment-inactivation" is formed, the inactivation rate of the HPV virus is as high as 90% or more, and the washing stability is excellent. The application provides a new solution for upgrading of medical protective textiles and daily hygiene products.
Owner:HANGZHOU GAOXI TECH CO LTD +2

Humanized monoclonal antibody and vaccines against measles virus

PCT designated stage expiredWO2025085916A1SsRNA viruses negative-senseViral antigen ingredientsMeasles Fusion ProteinVaccination
A chimeric monoclonal antibody (mAb 77.1) neutralizes measles fusion protein and its cryo-EM structure in complex with MeV F in the prefusion conformation. Vaccine compositions using MeV F protein or its ectodomain are mutated to have stabilized pre-fusion conformation. Vaccine compositions may be varied, targeting other paramyxoviruses; they are mutated forms of paramyxovirus F protein with mutations at specific positions on the protein. Thermostable full-length MeV fusion proteins (FFLs) induce protective immunity and neutralizing antibodies in vivo. Vaccination with the FFL induces neutralization titer higher than with live vaccine, providing robust humoral response, likely protective also for individuals with impaired cellular immunity. The 8 specific mAbs, alone or combined with mAb 77, neutralize post fusion transition of MeV fusion protein, interrupting the F refolding process and preventing conformational changes required for membrane fusion and viral entry: mAbs G3, F3, E11, 9E1D3, H8, 10H2G3, D9, and Y10F.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +4

Application of radix tetrastigme extract in preparation of medicine for resisting Crimean-Congo hemorrhagic fever virus

The invention discloses application of a radix tetrastigme extract in preparation of a medicine for resisting Crimean-Congo hemorrhagic fever virus, and belongs to the technical field of medicine. The anti-CCHFV effect of the radix tetrastigme extract is evaluated on the cellular level by utilizing a CCHFV virus-like particle system capable of simulating virus endocytosis and transcriptional activity, and the result shows that the radix tetrastigme extract has remarkable antiviral activity, is dose-dependent, and has a good application prospect. The antiviral activity mechanism of the radix tetrastigme extract is related to virus cell entry and virus transcription stages. The radix tetrastigme extract provided by the invention shows the activity of inhibiting the CCHFV, and has a wide prospect of being developed into a medicine for treating human CCHFV infection.
Owner:WUHAN BOTANICAL GARDEN CHINESE ACAD OF SCI +1